Plain-English translation of NCT07787091 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia A research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing , an experimental new medication designed to help treat hemophilia A, a condition where blood doesn't clot properly. The study has two parts: first, healthy adults will receive a single dose to make sure the medication is safe and well-tolerated, and second (if results support it), adults with hemophilia A will receive multiple doses to see if the treatment works for them.
Hemophilia A is a serious bleeding disorder that limits patients' treatment options. This medication is being developed as a potential new way to help improve blood clotting in people with this condition.
You likely qualify if…
You likely don't qualify if…
In Phase 1, you would receive either a single injection of the medication or a placebo (inactive substance) under the skin. Researchers would then monitor you to check for any side effects and see how your body handles the medication. If Phase 1 results are positive and you have hemophilia A, you could potentially join Phase 2, where you would receive multiple doses of the medication over time with ongoing safety monitoring.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
Singapore